← Insider Monitor
MANNKIND CORP logo
MNKD

MANNKIND CORP

Nasdaq · Pharmaceutical Preparations

2
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

MannKind Corporation develops and commercializes inhaled therapies for diabetes and other endocrine and orphan lung diseases, including Afrezza, an inhaled rapid-acting insulin taken at mealtime.

Industry
Pharmaceutical Preparations
Headquarters
Danbury, CT
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Binder Steven B.InsiderSell$128KSep 10, 2026
Binder Steven B.InsiderSell$159KAug 7, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for MNKD.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable MNKD activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.